I have reread the Preferred Stock and Warrant info

I have reread the Preferred Stock and Warrant info and I admit I can’t summarize it into clear cut specifics but let me take an over-simplified shot at it. In a worse-case scenario where IPIX would need to tap into the entire $10M let’s say this MFO ends up paying .15/share when all is said and done after converting warrants into common shares. A key part of this deal is that there are limits on how much and when shares can be sold to insure that shares are not flooded on the market. Aspire and now this MFO are neither good guys or bad guys they are simply needed as a cost of doing business until revenue flows into IPIX in the form of upfront payments and eventually royalty payments. $10M at .15 is 67M shares. As of 6/30/18 there were 163.1M shares outstanding. In a worse-case scenario we would be at 230M outstanding shares. IPIX burn rate was $12M/year with expensive phase2 trials taking place. There are NO IPIX FDA trials currently taking place so this $10M represents AT LEAST 10 months of expenses and more likely 12-14 months. This deal gives IPIX breathing room to finalize at least a Brilacidin deal and possibly a second license deal with Prurisol. A Brilacidin royalty deal for B-OM and B-IBD addressing two $1B+ markets will easily spike the value in the $690M- $1.38B valuation range. This example translates to a $3-$6 share price. Again this is just for the Brilacidin deal. A Prurisol license deal at least doubles that number. The question for investors is do they believe Leo can get a B deal done in the next 10-12 months? I still believe B deal this quarter and P deal first half 2019. If the Term Sheet deal does get finalized this quarter than most of the $10M will not be needed and the total outstanding shares will be less than 200M which would equate to an even higher share price than the above example. Seems like a no-brainer risk/reward to me. JMHO. Btw, I believe any poster that is spewing FUD regarding toxic financing, articles about shady shark financing, comparing a biotech Term Sheet deal to a Venture Capital deal (apples to oranges) or any other FUD is either not looking at the big picture or is simply a baby-face (pretend to be a long with positive posts) in a trading gang and I am calling them out for what they are as pure bullshit.